Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1)

Rutter, M K; Prais, H R; Charlton-Menys, V; Gittins, M; Roberts, C; Davies, R R; Moorhouse, A; Jinadev, P; France, M; Wiles, P G; Gibson, J M; Dean, J; Kalra, P A; Cruickshank, J K; Durrington, P N

Diabet Med. 2011;28(1):100-8.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally


AIMS: To compare the renal effects of low- vs. high-dose atorvastatin in patients with Type 2 diabetes mellitus and optimally managed early renal disease. METHODS: We compared the 2-year progression of nephropathy in a double-blind randomized controlled trial of atorvastatin 80 mg/day (n = 60) vs. 10 mg/day (n = 59) in patients with Type 2 diabetes with microalbuminuria or proteinuria [mean (sd): age 64 years (10 years); HbA(1c) 7.7% (1.3%), 61 mmol/mol (10 mmol/mol); blood pressure 131/73 mmHg; renin-angiotensin system blocker use > 80%; dual blockade > 67%] recruited from diabetes clinics in Greater Manchester. RESULTS: Over (mean) 2.1 years of follow-up, the Modification of Diet in Renal Disease estimated glomerular filtration rate declined by 3 ml min(-1) 1.73 m(-2) in the combined group. The mean (95% CI) between-group difference during follow-up was not significant [2.2 ml min(-1) 1.73 m(-2) (-1.1 to 5.4 ml min(-1) 1.73: m(-2) ), P = 0.20] after adjusting for baseline differences in renal function; positive difference favours 80 mg dose. Similarly, there was no significant difference in creatinine clearance by Cockcroft and Gault [2.5 ml/min (-2.4 to 7.3 ml/min), P = 0.32]; serum creatinine/24-h urine collections [4.0 ml/min (-4.8 to 12.7 ml/min), P = 0.38]; cystatin C (P = 0.69); or 24-h urine protein or albumin excretion (P = 0.92; P = 0.93). We recorded no significant between-group differences in deaths or adverse events. CONCLUSIONS: In patients with Type 2 diabetes with early renal disease, we found no statistical difference in renal function between those taking high- or low-dose atorvastatin over 2 years. We cannot exclude a beneficial effect of < 1.6 ml min(-1) 1.73 m(-2) year(-1) on Modification of Diet in Renal Disease estimated glomerular filtration rate, or if blood pressure management or if renin-angiotensin system blocker use had not been optimized.

Bibliographic metadata

Type of resource:
Content type:
Published date:
Journal title:
Start page:
End page:
Digital Object Identifier:
ISI Accession Number:
Related website(s):
  • Related website
General notes:
  • Rutter, M K Prais, H R Charlton-Menys, V Gittins, M Roberts, C Davies, R R Moorhouse, A Jinadev, P France, M Wiles, P G Gibson, J M Dean, J Kalra, P A Cruickshank, J K Durrington, P N Research Support, Non-U.S. Gov't England Diabetic medicine : a journal of the British Diabetic Association Diabet Med. 2011 Jan;28(1):100-8. doi: 10.1111/j.1464-5491.2010.03139.x.
Access state:

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
Created by:
Gibson, Martin
15th January, 2012, 14:43:55
Last modified by:
Gibson, Martin
Last modified:
27th October, 2015, 01:42:53

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.